Harry Kane leads Bayern to 2-1 win over Real Madrid in 1st leg of Champions League quarterfinals

MADRID (AP) — Harry Kane delivered for Bayern Munich on his return from injury, scoring a goal and helping set up another in his team's 2-1 win at Real Madrid in the first leg of the Champions League quarterfinals on Tuesday.

Kylian Mbappé scored Madrid's goal after the visitors had taken a two-goal lead at the Santiago Bernabeu stadium. Veteran goalkeeper Manuel Neuer came up big for Bayern with several key saves to keep the German champions with the first-leg edge.

Kane had been listed as a gameday decision after missing the team’s Bundesliga match last weekend because of an ankle injury.

“We knew that coming to Madrid and trying to get a result is always difficult," Kane told TNT Sports. "We played some really good stuff and we could have done even better — maybe the final ball, the final finish, we had some good chances. But credit to Madrid as well.”

The result left Bayern with an edge ahead of the second leg in Germany next week as it tries to reach the Champions League semifinals for the first time since 2023-24, when it was eliminated by eventual champion Madrid.

“We are still alive, clearly,” Madrid coach Álvaro Arbeloa said. “We are one goal away. We have shown that we can win anywhere. We showed it with the scoring chances that we had against an opponent that we knew was going to make it difficult for us.”

Arsenal won 1-0 at Sporting Lisbon in the other quarterfinal on Tuesday.

On Wednesday, Barcelona will host Spanish rival Atletico Madrid, and Liverpool will visit defending champion Paris Saint-Germain.

Madrid and Bayern are playing their sixth knockout-stage meeting in 14 seasons, with the Spanish powerhouse having won four of their five two-leg matchups since the 2011-12 season.

Kane participated in the build up of Bayern’s first goal in the 41st minute, exchanging passes with Serge Gnabry who ultimately fed a through ball for Luis Díaz inside the area. The Colombia forward calmly sent a low shot past Madrid goalkeeper Andriy Lunin.

Kane scored himself in the 46th with a nice one-timer from the top of the area, firmly finding the corner with a low strike. It was his 11th Champions League goal, equaling his best scoring season in the European tournament. He finished with 11 goals in 2024-25.

Kane has scored 22 Champions League goals since the start of the 2024-25 season, the most of anybody.

Mbappé scored his 20th Champions League goal since the start of the 2024-25 season in the 74th, finding the net from close range after a pinpoint low cross by Trent Alexander-Arnold.

Mbappé leads the scoring this season with 14 goals, which is double the forward’s total last season. He is three goals shy of the most goals in a single Champions League campaign achieved by Cristiano Ronaldo with Madrid in 2013-14.

Vinícius Júnior had one of Madrid’s best chances in a one-on-one situation with Neuer in the 61st, but the Brazil forward couldn’t get past the Bayern goalkeeper and his attempt hit the outside of the net. A few minutes later, Neuer — who had nine saves in total and was named the man of the match — dived to his right to make a nice stop on a shot by Mbappé.

Neuer had already made two tough saves to keep Madrid from finding the net in the first half on other attempts by Mbappé and Vinícius.

“I had the feeling that he was in very good shape and we needed him — not only for his experience, but his quality,” Bayern coach Vincent Kompany said of the 40-year-old Neuer. “He reacted in very difficult stages of this game. With his work rate in training, I’m not surprised.”

Madrid defender Álvaro Carreras made a goal-line clearance on a shot by Dayot Upamecano in the first-half.

It was a bad touch by Carreras near midfield that led to Bayern's second goal.

“We went out for the second half and they immediately scored," Madrid defender Antonio Rüdiger said. “I’d say we gifted Bayern both their goals here. We need to do better.”

Bayern lost to Inter Milan in the quarterfinals last season. Record 15-time European champion Madrid was eliminated by Arsenal in the last eight last year.

Bayern is unbeaten in its last 14 games in all competitions, with 12 wins. Madrid was coming off a 2-1 loss at Mallorca on Saturday that hurt its La Liga title hopes.

AP soccer: https://apnews.com/hub/soccer

Bayern's goalkeeper Manuel Neuer makes a save before Real Madrid's Raul Asencio can score during the Champions League quarterfinal first leg soccer match between Real Madrid and Bayern Munich in Madrid, Spain, Tuesday, April 7, 2026. (AP Photo/Jose Breton)

Bayern's goalkeeper Manuel Neuer heads the ball to save before Real Madrid's Vinicius Junior, left, can score during the Champions League quarterfinal first leg soccer match between Real Madrid and Bayern Munich in Madrid, Spain, Tuesday, April 7, 2026. (AP Photo/Jose Breton)

Real Madrid's Alvaro Carreras, right, and Bayern's Luis Diaz challenge for the ball during the Champions League quarterfinal first leg soccer match between Real Madrid and Bayern Munich in Madrid, Spain, Tuesday, April 7, 2026. (AP Photo/Bernat Armangue)

Bayern's Harry Kane celebrates scoring his side's second goal during the Champions League quarterfinal first leg soccer match between Real Madrid and Bayern Munich in Madrid, Spain, Tuesday, April 7, 2026. (AP Photo/Jose Breton)

Real Madrid's Vinicius Junior reacts during the Champions League quarterfinal first leg soccer match between Real Madrid and Bayern Munich in Madrid, Spain, Tuesday, April 7, 2026. (AP Photo/Bernat Armangue)

Real Madrid's Kylian Mbappe scores his side's opening goal during the Champions League quarterfinal first leg soccer match between Real Madrid and Bayern Munich in Madrid, Spain, Tuesday, April 7, 2026. (AP Photo/Bernat Armangue)

Bayern's Harry Kane tries to score during the Champions League quarterfinal first leg soccer match between Real Madrid and Bayern Munich in Madrid, Spain, Tuesday, April 7, 2026. (AP Photo/Bernat Armangue)

Bayern's Harry Kane celebrates scoring his side's second goal during the Champions League quarterfinal first leg soccer match between Real Madrid and Bayern Munich in Madrid, Spain, Tuesday, April 7, 2026. (AP Photo/Jose Breton)

Bayern's Harry Kane celebrates scoring his side's second goal during the Champions League quarterfinal first leg soccer match between Real Madrid and Bayern Munich in Madrid, Spain, Tuesday, April 7, 2026. (AP Photo/Jose Breton)

Real Madrid's Kylian Mbappe reacts during a La Liga soccer match between Mallorca and Real Madrid in Palma de Mallorca, Spain, Saturday, April 4, 2026. (AP Photo/Jose Breton)

Real Madrid's Vinicius Junior in action in front of Mallorca's Pablo Maffeo during a La Liga soccer match between Mallorca and Real Madrid in Palma de Mallorca, Spain, Saturday, April 4, 2026. (AP Photo/Jose Breton)

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Jun 8, 2026--

Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions for the pharmaceutical, biotechnology, and life sciences industries, today introduced Deora™, a new proprietary pen injector platform targeting incretin-based therapies, as well as supporting other originator and biosimilar drug development programs.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608096966/en/

Deora™ is a multi-use, fixed-dose pen injector featuring a simple pull-push mechanism for dose setting and delivery: the user pulls to set the dose, then pushes to inject. This intuitive sequence eliminates the need for manual dose selection, reducing common sources of use error and supporting consistent drug delivery across multiple administrations. The platform is compatible with standard 1.5 mL and 3 mL cartridges and accommodates fixed-dose volumes up to 0.75 mL.

“With Deora™, we are broadening our product offering in therapeutic areas experiencing strong global demand and favorable market momentum,” said Michele Monico, President of Drug Delivery Systems and In Vitro Diagnostics at Stevanato Group. "We believe there is space for a simple, multi-use device that enhances the patient experience while simultaneously reducing the pressure on supply chain scale-up. Our belief has been supported by early customer interest, and we are providing our pharmaceutical partners with evaluation units to support early-stage testing and development activities.”

The device architecture provides flexibility across multiple fixed-dose configurations while minimizing the need for design changes across variants. In addition, it is designed to integrate seamlessly into existing supply chains, enabling efficient industrialization and scalable manufacturing.

“Deora™ further expands Stevanato Group’s proprietary portfolio of drug delivery devices, providing a solution designed for multi-dose therapies requiring consistent administration and ease of use in a familiar pen format,” added Michele Monico. “Customers can now choose from different hand-held device platforms – Alina®, Aidaptus®, and Deora™ – to address a broad range of therapeutic needs.”

Deora™ leverages Stevanato Group’s established manufacturing capabilities, with production aligned to support future commercialization. Drawing on its end-to-end expertise across glass manufacturing, analytical services, and device engineering, Stevanato Group offers fully integrated solutions that can simplify development for pharmaceutical partners.

Together, these characteristics position Deora™ as a platform intended to support partners as they advance early development programs and prepare for future scale-up.

About Stevanato Group

Founded in 1949, Stevanato Group is a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. The Group delivers an integrated, end-to-end portfolio of products, processes and services that address customer needs across the entire drug life cycle at each of the development, clinical and commercial stages. Stevanato Group’s core capabilities in scientific research and development, its commitment to technical innovation and its engineering excellence are central to its ability to offer value added solutions to clients. To learn more, visit: www.stevanatogroup.com.

Forward-Looking Statements

This press release may include forward-looking statements. The words “strong”, “experiencing”, “believe”, “are providing”, “position”, “advance”, “intended”, “prepare”, “future”, and similar expressions (or their negative) identify certain of these forward-looking statements. These forward-looking statements are statements regarding the Company's intentions, beliefs or current expectations concerning, among other things, the investments the Company expects to receive, the expansion of manufacturing capacity, the Company’s plans regarding its presence in the U.S. market, business strategies, the Company’s capacity to meet future market demands and support preparedness for future public health emergencies, and results of operations. The forward-looking statements in this press release are based on numerous assumptions regarding the Company’s present and future business strategies and the environment in which the Company will operate in the future. Forward-looking statements involve inherent known and unknown risks, uncertainties and contingencies because they relate to events and depend on circumstances that may or may not occur in the future and may cause the actual results, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements. Many of these risks and uncertainties relate to factors that are beyond the Company's ability to control or estimate precisely, such as future market conditions, currency fluctuations, the behavior of other market participants, the actions of regulators and other factors such as the Company's ability to continue to obtain financing to meet its liquidity needs, changes in the political, social and regulatory framework in which the Company operates or in economic or technological trends or conditions. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. Except as required by law, the company assumes no obligation to update any such forward-looking statements.

Deora™ is Stevanato Group’s multi-use, fixed-dose pen injector designed for subcutaneous drug delivery in therapies such as diabetes and weight management. Featuring an intuitive pull‑push mechanism, the device simplifies dose administration by eliminating the need for manual dose selection: users pull to set the dose and push to inject, supporting consistent delivery across multiple administrations. The platform accommodates fixed-dose volumes up to 0.75 mL and is compatible with standard 1.5 mL and 3 mL cartridges, offering flexibility across a range of therapeutic applications. Engineered with patient usability in mind, Deora™ provides tactile, visual, and audible feedback during operation, helping reduce common sources of use error. Its architecture is designed to integrate seamlessly into existing supply chains, enabling efficient industrialization and scalable manufacturing for pharmaceutical partners